← All trials
NCT05405868
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- May 30, 2026
- Completion date
- Nov 30, 2026
- First posted
- Jun 6, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 496
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- University of LondonOverall official - principal investigator
- National Institute for Health Research, United KingdomCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.